231 results about "Acyltransferase" patented technology

Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 10% arachidonic acid (ARA, an ω-6 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases, and optionally comprise various native desaturase and acyltransferase knockouts to enable synthesis and high accumulation of ARA. Production host cells are claimed, as are methods for producing ARA within said host cells.

Plant nucleic acid compositions encoding polypeptide products with diacylglyceride acyltransferase (DGAT) activity, as well as the polypeptide products encoded thereby and methods for producing the same, are provided. Methods and compositions for modulating DGAT activity in a plant, particularly DGAT activity in plant seeds, and transgenic plants with altered DGAT activity are provided. Such plants and seeds are useful in the production of human food and animal feedstuff, and have several other industrial applications. Also provided are methods for making triglycerides and triglyceride compositions, as well as the compositions produced by these methods. The subject methods and compositions find use in a variety of different applications, including research, medicine, agriculture and industry.

Glycerol-3-phosphate o-acyltransferase (GPAT) participates in the first step of oil biosynthesis and is expected to play a key role in altering the quantity of long-chain polyunsaturated fatty acids (PUFAs) produced in oils of oleaginous organisms. The present application provides a nucleic acid fragment isolated from Mortierella alpina encoding a GPAT that is suitable for use in the manufacture of oils enriched in omega fatty acids in oleaginous organisms. Most desirably, the substrate specificity of the instant GPAT will be particularly useful to enable accumulation of long-chain PUFAs having chain lengths equal to or greater than C₂₀ in oleaginous yeast, such as Yarrowia lipolytica.

The invention discloses recombinant saccharomyces cerevisiae for producing dammarenediol and protopanoxadiol using xylose and a construction method. The construction method comprises the steps of replacing a promoter of a saccharomyces cerevisiae xylulokinase gene XKS1 with a promoter PFBA1 by virtue of a homologous recombination method, introducing xylose reductase XYL1 and a xylitol dehydrogenase XYL2 expression cassette, increasing the activities of transketolase TKL1 and transaldolase TAL1 so as to obtain recombinant bacteria 1, introducing a farnesyl-diphosphate farnesyltransferase gene ERG9, a squalene monooxygenase gene ERG1 and a dammarenediol synthase gene DS into the recombinant bacteria 1 so as to obtain recombinant bacteria 2, and introducing a nicotinamide adenine dinucleotide-hydroxymethylglutaryl coenzyme A reductase gene NADH-HMGr, farnesyl diphosphatesynthase ERG20 and a protopanoxadiol synthase-cytochrome P450 reductase fusion protein gene PPDS-ATR1 into the recombinant bacteria 2, so as to obtain recombinant bacteria 3. According to the recombinant saccharomyces cerevisiae, dammarenediol and protopanoxadiol can be artificially synthesized by virtue of xylose.

Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

The present invention pertains to the recombinant manufacture of polyunsaturated fatty acids. Specifically, it relates to acyltransferase polypeptides, polynucleotides encoding said acyltransferases as well as vectors, host cells, non-human transgenic organisms containing said polynucleotides. Moreover, the present invention contemplates methods for the manufacture of polyunsaturated fatty acids as well as oils obtained by such methods.

The present invention relates to diacylglycerol acyltransferase genes and proteins, and methods of their use. In particular, the invention describes genes and proteins that exhibit both long-chain acyltransferase and acetyltransferase activity. The present invention encompasses both native and recombinant wild-type forms of the transferase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type transferase. The present invention also relates to methods of using diacylglycerol acyltransferase genes and proteins, including in their expression in transgenic organisms and in the production of acetyl-glycerides in plant oils, and in particular seed oils.

The present invention relates to use of gene engineering in modifying antibiotic ingredient, more specificly it refer to blocking and destroying 3-O-acyltransferase which take part in the production of component II and III of bitespiramycin-producing bacteria. The engineered bacteria is obtained by homologous gene double exchange and employs 4'' -isovalerylspiramycin I as main ingredient. The engineered bacteria can simplify the production process, lower the production cost and control the quality standard.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

The present invention relates to compositions comprising acyltransferase nucleic acid molecules for altering lipids on the surface of plants, and related methods. In particular, the present invention provides compositions and methods for increasing the amount of free fatty acids, acylglycerols, and other lipids on the surface of a plant. In a preferred embodiment, the present invention relates to increasing activity of a GPAT acyltransferase for altering lipid on the plant surface, for increasing surface lipids, for enhancing environmental stress tolerance, increasing resistance to biotic stress, and providing novel plant lipids for commercial products. In further embodiments, the present invention relates to using an Arabidopsis thaliana GPAT acyltransferase for altering lipid compounds on the surface of a plant.

The invention discloses a construction method of an engineering strain for producing tetrahydropyrimidine by a biological method and application of the engineering strain in tetrahydropyrimidine production. According to the engineering strain provided by the invention, heterologous expression of an tetrahydropyrimidine synthetic gene cluster of a marine microorganism salinicola salinia is utilized, so that aminobutyric acid acetyltransferase, diaminobutyric acid aminotransferase and tetrahydropyrimidine synthetase are highly expressed in series in escherichia coli, and then sodium aspartate is catalyzed through an enzymatic reaction to generate tetrahydropyrimidine. The bioconversion method of the tetrahydropyrimidine has the characteristics of mild reaction temperature, simple process and high conversion rate.

The invention relates to cloning, sequencing, analysis and functional study of a biosynthetic gene cluster of a natural product FR901464 which has anti-tumor activity and is generated from pseudomonas as well as the application thereof. The whole gene cluster contains 20 genes: five polyketide synthase genes, one hybrid polyketide/non-ribosomal polypeptide synthase gene, one non-ribosomal polypeptide synthase gene, three independent acyltransferase genes, four genes related to polyketide backbone alkylation, four post-modification genes and two control-related genes. The genetic operation of the biosynthetic gene can block the biosynthesis of FR901464. The provided gene and protein thereof can be used for genetic engineering, protein expression, enzyme catalysis reaction, and the like of the compound and can also be used for searching and discovering compounds that can be used in medicines, industry or agriculture or genes and proteins thereof.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

The invention discloses multipath composite neuraminic acid producing bacillus subtilis and an application thereof, and belongs to the field of genetic engineering. The expression levels of key enzymes, namely UDP-N-acetylglucosamine-2-epimerase, N-acetylglucosamine-6-phosphate isomerase, glucosamine-6-phosphoric acid-N-acetyltransferase, N-acetylglucosamine isomerase and N-acetylneuraminate synthase on genomes in three neuraminic acid synthesis paths are sequentially optimized by 10 promoters with different intensities, so that the protein synthesis pressure of enzyme expression on cells is reduced; and three neuraminic acids are further integrated into the same engineering bacillus subtilis, so that the bacillus subtilis with the increased N-acetylneuraminic acid yield is obtained, the neuraminic acid yield under the shake flask level reaches 10.4 g/L, and a foundation is laid for further increasing the NeuAc yield of the bacillus subtilis.